Midostaurin

Overview

Midostaurin is a multi-targeted kinase inhibitor used in the treatment of acute myeloid leukemia and certain other hematological malignancies. It works by interfering with the action of FLT3 and other kinases involved in cancer cell proliferation.

API suppliers (1)

Suppliers of Midostaurin backed by a verifiable FDA Type II Drug Master File. Source: FDA quarterly DMF list.

• BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO LTD

Patent & exclusivity (US)

Per the FDA Orange Book (3 approved US products), the latest listed US patent on Midostaurin expires 2 Dec 2030. Generic API sourcing typically opens up once these lapse.

Therapeutic areas